Objective. This study is aimed to reveal the possible mechanisms of artemisinin in the treatment of ulcerative colitis (UC) through bioinformatics analysis and experimental verification in UC model rats. Methods. Firstly, we searched two microarray data of the Gene Expression Omnibus (GEO) database to explore the dierentially expressed genes (DEGs) between UC samples and normal samples. Then, we selected DEGs for gene ontology (GO) function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. The acute UC model of rats was established by using 3.5 dextran sulfate sodium (DSS) for 10days to verify the core pathway. Finally, we evaluated the therapeutic effect of artemisinin at the molecular level and used metabonomics to study the endogenous metabolites in the rat serum. Results. We screened in the GEO database and selected two eligible microarray datasets, GSE36807 and GSE9452. We performed GO function and KEGG pathway enrichment analyses of DEGs and found that these DEGs were mainly enriched in the inflammatory response, immune response, and IL-17 and NF-κB signaling pathways. Finally, we verified the IL-17 signaling pathway and key cytokines, and ELISA and immunohistochemical results showed that artemisinin could downregulate the expression of proinflammatory cytokines such as IL-1β and IL-17 in the IL-17 signaling pathway and upregulate the expression of the anti-inflammatory cytokine PPAR-γ. Metabolomics analysis showed that 33 differential metabolites were identified in the artemisinin group (AG) compared to the model group (MG). Differential metabolites were mainly involved in alanine, aspartate, and glutamate metabolism and synthesis and degradation of ketone bodies. Conclusion. In this study, we found that artemisinin can significantly inhibit the inflammatory response in UC rats and regulate metabolites and related metabolic pathways. This study provides a foundation for further research on the mechanism of artemisinin in the treatment of UC.
Colorectal adenoma (CRA) represents a pathological condition characterized by the aberrant development of intestinal epithelial cells and alterations in cellular differentiation within the colorectal mucosal epithelium, posing an increased risk for malignant transformation if not adequately addressed. Curcumin has been shown to exhibit a range of therapeutic effects across various diseases, which motivated this investigation utilizing C57BL/6 mice as a model system. Methodologies including hematoxylin‐eosin staining (HE), western blot analysis, RT‐PCR, immunofluorescence, and electron microscopy were employed to evaluate proteins associated with the AMPK/mTOR/ULK1 signaling pathway. The study specifically examined variations in key autophagy‐related proteins such as Beclin‐1, LC3, P62, alongside intestinal junction proteins Occludin, ZO‐1, and Claudin‐1. This study seeks to elucidate whether curcumin can influence autophagy‐related mechanisms in intestinal mucosal epithelial cells affected by colorectal adenoma to achieve potential therapeutic outcomes.
5 November 2026 in Immunity, Inflammation and Disease
Background: Irritable bowel syndrome with diarrhea (IBS‐D) remains a challenging condition to manage due to its chronic nature and the limited long‐term efficacy of current treatments. The traditional Chinese herbal formula Jiangfu Zhixie (JFZX) has shown clinical benefits, but its underlying mechanisms remain unclear. Aim: This study aimed to investigate the therapeutic effects of JFZX on IBS‐D and elucidate its molecular mechanisms, focusing on macrophage polarization and the HIF‐1α‐glycolysis axis. Methods: An IBS‐D mouse model was established by senna leaf infusion combined with restraint stress. Mice were treated with varying doses of JFZX or pinaverium bromide (positive control) for 14 days. Diarrhea symptoms, visceral hypersensitivity, and intestinal barrier integrity were assessed. Single‐cell RNA sequencing (scRNA‐seq) was performed on colon tissues to analyze cellular composition and intercellular interactions. In vitro, LPS‐stimulated RAW264.7 macrophages were treated with JFZX‐medicated serum to evaluate M1 polarization, cytokine secretion (IL‐1β, TNF‐α), and expression of HIF‐1α and glycolysis‐related proteins (GLUT1, LDHA). Results: JFZX treatment significantly ameliorated diarrhea, reduced visceral hypersensitivity, and restored intestinal barrier integrity in IBS‐D mice, accompanied by upregulation of tight junction proteins ZO‐1 and Occludin. scRNA‐seq revealed that JFZX reshaped the colonic cellular landscape, attenuating myeloid‐epithelial interactions and reducing the proportion of pro‐inflammatory M1‐like macrophages. Mechanistically, HIF‐1α was identified as a key driver of M1 polarization in IBS‐D. JFZX suppressed HIF‐1α expression and its downstream glycolytic pathway (GLUT1, LDHA) both in vivo and in vitro, thereby inhibiting M1 macrophage polarization and decreasing IL‐1β and TNF‐α secretion in LPS‐stimulated macrophages. Conclusion: JFZX alleviates IBS‐D by inhibiting M1 macrophage polarization through suppression of the HIF‐1α‐glycolysis axis, highlighting its potential as a therapeutic agent for IBS‐D and identifying HIF‐1α as a promising target for intervention.